ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2028

Contribution of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia Rheumatica: A Controlled Study

Maxime Sondag1, Xavier Guillot2, Frank Verhoeven2, Clément Prati3, Hatem Boulahdour4 and Daniel Wendling5, 1Rheumatology, University Teaching Hospital, Besançon, France, 2Service de Rhumatologie, CHRU J Minjoz, Besançon, France, 3Service de Rhumatologie, CHU J Minjoz, Besancon, France, 4Nuclear Medicine, University Teaching Hospital, Besançon, France, 5Université de Franche-Comté, Besançon, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: 18FDG PET/CT scan, diagnosis and polymyalgia rheumatica

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Imaging of Rheumatic Diseases II: MRI, PET and CT

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Polymyalgia rheumatica (PMR) is a frequent inflammatory condition in elderly people. The place of imaging becomes important for positive and differential diagnosis like malignancy but there is no gold standard. We compared 18f-Fluoro-Dexoxyglucose Positron Emission Tomography (FDG-PET/CT) findings in patients with PMR and controls without rheumatologic disease.

Methods:

Forty-six patients with a diagnosis of PMR, according to 2012 ACR/ EULAR criteria, who have had a FDG-PET/CT have been included. For comparison, fifty-tree patients who have had a FDG-PET/CT for initial staging or follow-up of neoplasm were included as controls. 17 sites where analyzed on PET: 2 shoulders, 2 acromio-clavicular and 2 sterno-clavicular joints, 2 greater trochanters, 2 hips, 2 ischial tuberosities, 2 iliopectinal bursitis, 2 pubic symphysis enthesis and only the interspinous space with the most FDG uptake. We used the semi-quantitative scoring system, by Goerres and al. to evaluate visually FDG uptake (0 to 3 compared to liver uptake) into these sites. We calculated the FDG uptake score corresponding to the mean of intensity over all sites,  and the number of sites with significant uptake (FDG uptake 2 or 3) for each patient.

Results:

The two groups were comparable for the median patient age (68,9

for PMR vs. 68,1 years for controls). The characteristics of the patients of PMR group were 55% women, CRP 40,9mg/L, ESR 41,1mm, and an ACR/EULAR score without ultrasound of 4.78/6. Significant differences between the two groups were found for FDG uptake score and for number of sites with significant uptake (Table 1): 1.09 vs. 0.34, and 6.13 sites vs. 1.49 sites, p<0.0001.

With ROC curves analysis, we show that the presence of 3 or more sites with significant uptake is correlated with the diagnosis of PMR with 72% sensibility, 79% specificity [OR = 9.69]. For the FDG uptake score the cut off is 0.53 [Se 76%, Sp 79%; OR 12.1].

We found significant differences in all sites analyzed separately for FDG uptake score and number of sites with significant uptake compared to controls, particularly marked for shoulders, ischial tuberosities and interspinous bursitis (p<0.00001 for FDG uptake score).

Table 1.

 

 

FDG uptake score

(0 – 3)

Number of sites with significant uptake

(0 – 17)

PMR group (N=46)

1.09

[%CI 1.06-1.11]

6.13

[%CI 4.99-7.26]

Control group (N=53)

                 0.34

      [%CI 0.33-034]

1.49

[%CI 1.38-1.59]

p

p<0.0001

p<0.0001

Conclusion:

FDG-PET/CT for PMR diagnosis is useful: we found significant uptake in articular and peri-articular sites compared to controls particularly shoulders, ischial tuberosities and interspinous space. We propose the number of 3 sites with significant uptake and a FDG uptake score over 0.53 as cut-offs for the diagnosis of PMR.


Disclosure: M. Sondag, None; X. Guillot, None; F. Verhoeven, None; C. Prati, None; H. Boulahdour, None; D. Wendling, None.

To cite this abstract in AMA style:

Sondag M, Guillot X, Verhoeven F, Prati C, Boulahdour H, Wendling D. Contribution of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia Rheumatica: A Controlled Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/contribution-of-18f-fluoro-dexoxyglucose-positron-emission-tomography-for-the-diagnosis-of-polymyalgia-rheumatica-a-controlled-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contribution-of-18f-fluoro-dexoxyglucose-positron-emission-tomography-for-the-diagnosis-of-polymyalgia-rheumatica-a-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology